BBIO Stock Recent News
BBIO LATEST HEADLINES
NEW YORK, NY / ACCESSWIRE / June 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violations of federal securities laws. BridgeBio issued a press release on June 4, 2024, "announc[ing] sustained positive results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, demonstrating continued potential best-in-class efficacy and an encouraging safety profile.
NEW YORK, NY / ACCESSWIRE / June 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BridgeBio Pharma, Inc. ("BridgeBio" or "the Company") (NASDAQ:BBIO). Investors who purchased BridgeBio securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BBIO.
NEW YORK, NY / ACCESSWIRE / June 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BridgeBio Pharma, Inc. ("BridgeBio" or "the Company") (NASDAQ:BBIO). Investors who purchased BridgeBio securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BBIO.
NEW YORK, NY / ACCESSWIRE / June 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violations of federal securities laws. BridgeBio issued a press release on June 4, 2024, "announc[ing] sustained positive results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, demonstrating continued potential best-in-class efficacy and an encouraging safety profile.
NEW YORK, NY / ACCESSWIRE / June 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violations of federal securities laws. BridgeBio issued a press release on June 4, 2024, "announc[ing] sustained positive results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, demonstrating continued potential best-in-class efficacy and an encouraging safety profile.
- BridgeBio has surpassed its interim analysis enrollment target for its Phase 3 FORTIFY study of BBP-418 in individuals living with LGMD2I/R9, with top-line results from the interim analysis expected in 2025
NEW YORK--(BUSINESS WIRE)---- $BBIO #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BridgeBio Pharma, Inc. (“BridgeBio” or “the Company”) (NASDAQ: BBIO). Investors who purchased BridgeBio securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BBIO. Investigation Details: On June 5, 2024, BridgeBio issued a press release “announc[ing] sustained positive result.
PALO ALTO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on June 6, 2024, the compensation committee of BridgeBio's board of directors approved equity grants to 18 new employees in restricted stock units for an aggregate of 90,591 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on May 16, 2025, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan (the “Plan”).
NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. ("BridgeBio" or the "Company") (NASDAQ:BBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
PALO ALTO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that Neil Kumar, Ph.D., founder and CEO of BridgeBio, will present at the Goldman Sachs Annual Global Healthcare Conference in Miami, FL on Wednesday, June 12 at 3:20 pm EDT.